Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Molecular Diagnosis & Therapy
Erschienen in: Molecular Diagnosis & Therapy 2/2011

01.04.2011 | Current Opinion

The Influenza Pandemic of 2009

Lessons and Implications

verfasst von: Professor Paul Shapshak, Francesco Chiappelli, Charurut Somboonwit, John Sinnott

Erschienen in: Molecular Diagnosis & Therapy | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Influenza is a moving target, which evolves in unexpected directions and is recurrent annually. The 2009 influenza A/H1N1 pandemic virus was unlike the 2009 seasonal virus strains and originated in pigs prior to infecting humans. Three strains of viruses gave rise to the pandemic virus by antigenic shift, reassortment, and recombination, which occurred in pigs as ‘mixing vessels’. The three strains of viruses had originally been derived from birds, pigs, and humans. The influenza hemagglutinin (HA) and neuraminidase (NA) external proteins are used to categorize and group influenza viruses. The internal proteins (PB1, PB1-F2, PB2, PA, NP, M, and NS) are involved in the pathogenesis of influenza infection. A major difference between the 1918 and 2009 pandemic viruses is the lack of the pathogenic protein PB1-F2 in the 2009 pandemic strains, which was present in the more virulent 1918 pandemic strains. We provide an overview of influenza infection since 1847 and the advent of influenza vaccination since 1944. Vaccines and chemotherapy help reduce the spread of influenza, reduce morbidity and mortality, and are utilized by the global rapid-response organizations associated with the WHO. Immediate identification of impending epidemic and pandemic strains, as well as sustained vigilance and collaboration, demonstrate continued success in combating influenza.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Dis 2006; 12(1): 6–14CrossRef
2.
Bao Y, Bolotov P, Dernovoy D, et al. The Influenza Virus Resource at the National Center for Biotechnology Information. J Virol 2008; 82(2): 596–601PubMedCrossRef
3.
4.
Dawood FS, Jain S, Finelli L, et al.; Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360(25): 2605–15PubMedCrossRef
5.
Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, et al.; INER Working Group on Influenza. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009; 361: 680–9PubMedCrossRef
6.
Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 2009 influenza A (H1N1) infection in Canada; Canadian Critical Care Trials Group H1N1 Collaborative. JAMA 2009 Nov 4; 302(17): 1872–9PubMedCrossRef
7.
Lipsitch M, Lajous M, O’Hagan JJ, et al. Use of cumulative incidence of novel influenza A/H1N1 in foreign travelers to estimate lower bounds on cumulative incidence in Mexico. PLoS One 2009 Sep 9; 4(9): e6895PubMedCrossRef
8.
9.
10.
Morens DM, Taubenberger JK, Fauci AS. The 2009 H1N1 pandemic influenza virus: what next? MBio 2010; 1(4): e00211–10PubMedCrossRef
11.
12.
Harris KM, Maurer J, Kellermann AL. Influenza vaccine: safe, effective, and mistrusted. N Engl J Med 2010; 363: 2183–5PubMedCrossRef
13.
Hampson AW, Mackenzie JS. Preparing for an influenza epidemic: the influenza viruses. Med J Aust 2006; 185: S39–43PubMed
14.
Beran GW. Disease and destiny: mystery and mastery. Prev Vet Med 2008 Sep 15; 86(3-4): 198–207PubMedCrossRef
15.
Chow A, Ma S, Ling AE, et al. Influenza-associated deaths in tropical Singapore. Emerg Infect Dis 2006; 12: 114–21PubMedCrossRef
16.
Cruveilhier L. Action du sérum antipneumococcique au cours de la pneumonie et dans les complications de la grippe. Ann Inst Pasteur (Paris) 1919; 33: 448–61
17.
Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008; 198: 962–70PubMedCrossRef
18.
Bishop JF, Murnane MP, Owen R. Australia’s winter with the 2009 pandemic influenza A (H1N1) virus. N Engl J Med 2009; 361: 2591–4PubMedCrossRef
19.
Lessler J, Reich NG, Cummings DAT, and the New York City Department of Health and Mental Hygiene Swine Influenza Investigation Team. Outbreak of 2009 pandemic influenza A (H1N1) at a New York City school. N Engl J Med 2009; 361: 2628–36PubMedCrossRef
20.
Cauchemez S, Donnelly CA, Reed C, et al. Household transmission of 2009 pandemic influenza A (H1N1) virus in the United States. N Engl J Med 2009; 361: 2619–27PubMedCrossRef
21.
Ito T, Nelson J, Couceiro SS, et al. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J Virol 1998; 72: 7367–73PubMed
22.
Easterday BC, Van Reeth K. Swine influenza. In: Straw BE, D’Allaire SD, Mengeling WL, editors. Diseases of swine. 8th ed. Ames (IA): Iowa State University Press, 1999: 277–90
23.
Thacker E, Janke B. Swine influenza virus: zoonotic potential and vaccination strategies for the control of avian and swine influenzas. J Infect Dis 2008; 197: S19–24PubMedCrossRef
24.
Kothalawala H, Toussaint MJ, Gruys E. An overview of swine influenza. Vet Q 2006; 28: 46–53PubMedCrossRef
25.
Shinde V, Bridges CB, Uyeki TM, et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005–200. N Engl J Med 2009; 360: 1–10CrossRef
26.
Olsen CW. The emergence of novel swine influenza viruses in North America. Virus Res 2002; 85: 199–210PubMedCrossRef
27.
Lekcharoensuk P, Lager KM, Vemulapalli R, et al. Novel swine influenza virus subtype H3N1, United States. Emerg Infect Dis 2006; 12: 787–92PubMedCrossRef
28.
Shin JY, Song MS, Lee EH, et al. Isolation and characterization of novel H3N1 swine influenza viruses from pigs with respiratory diseases in Korea. J Clin Microbiol 2006; 44: 3923–7PubMedCrossRef
29.
Karasin AI, Schutten MM, Cooper LA, et al. Genetic characterization of H3N2 influenza viruses isolated from pigs in North America, 1977–1999: evidence for wholly human and reassortant virus genotypes. Virus Res 2000; 68: 71–85PubMedCrossRef
30.
Webby RJ, Swenson SL, Krauss SL, et al. Evolution of swine H3N2 influenza viruses in the United States. J Virol 2000; 74: 8243–51PubMedCrossRef
31.
Karasin AI, West K, Carman S, et al. Characterization of avian H3N3 and H1N1 influenza A viruses isolated from pigs in Canada. J Clin Microbiol 2004; 42: 4349–54PubMedCrossRef
32.
Campitelli L, Donatelli I, Foni E, et al. Continued evolution of H1N1 and H3N2 influenza viruses in pigs in Italy. Virology 1997; 232: 310–8PubMedCrossRef
33.
Kamps BS, Reyes-Terán G. Chapter 1: influenza 2006. In: Kamps BS, C Hoffmann C, W Preiser W, editors. Influenza report 2006 [online]. Available from URL: http://​www.​influenzareport.​com [Accessed 2011 Apr 1]
34.
Dias A, Bouvier D, Crépin T, et al. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 2009; 458: 914–8PubMedCrossRef
35.
Li OT, Chan MC, Leung CS, et al. Full factorial analysis of mammalian and avian influenza polymerase subunits suggests a role of an efficient polymerase for virus adaptation. PLoS One 2009 May 21; 4(5): e5658PubMedCrossRef
36.
Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009; 459: 931–40PubMedCrossRef
37.
Guilligay D, Tarendeau F, Resa-Infante P, et al. The structural basis for cap binding by influenza virus polymerase subunit PB2. Nat Struct Mol Biol 2008; 15(5): 500–6PubMedCrossRef
38.
Burgui I, Angüez E, Sonenberg N, et al. Influenza virus mRNA translation revisited: is the eIF4E cap-binding factor required for viral mRNA translation? J Virol 2007; 81: 12427–38PubMedCrossRef
39.
Conenello GM, Palese P. Influenza A virus PB1-F2: a small protein with a big punch. Cell Host Microbe 2007; 2: 207–9PubMedCrossRef
40.
Conenello G, Zamarin D, Perrone LA, et al. A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence. PLoS Pathog 2007; 3: 1414–21PubMedCrossRef
41.
Khanna M, Gupta N. Influenza A (H1N1) pandemic: preparedness and clinical management. Ind J Exp Biol 2009; 47: 929–32
42.
McAuley JL, Hornung F, Boyd KL, et al. Expression of the 1918 influenza A virus PB1-F2 enhances the pathogenesis of viral and secondary bacterial pneumonia. Cell Host Microbe 2007; 2: 2240–9CrossRef
43.
Trifonov V, Racaniello V, Rabadan R. The contribution of the PB1-F2 protein to the fitness of influenza A viruses and its recent evolution in the 2009 influenza A (H1N1) pandemic virus. PLoS Curr 2009 Aug 21; 1: RRN1006PubMedCrossRef
44.
Schnitzler SU, Schnitzler P. An update on swine-origin influenza virus A/H1N1: a review. Virus Genes 2009; 39: 279–92PubMedCrossRef
45.
Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325: 197–201PubMedCrossRef
46.
47.
Shen J, Ma J, Wang Q. Evolutionary trends of A (H1N1) influenza virus hemagglutinin since 1918. PLoS One 2009 Nov 17; 4(11): e7789PubMedCrossRef
48.
Suarez DL, Senne DA, Banks J, et al. Recombination resulting in virulence shift in avian influenza outbreak, Chile. Emerg Infect Dis 2004; 10: 693–9PubMedCrossRef
49.
Santibañez S, Fiore AE, Merlin TL, et al. A primer on strategies for prevention and control of seasonal and pandemic influenza. Am J Public Health 2009 Oct; 99Suppl. 2: S216–24PubMedCrossRef
50.
Neumann G, Kawaoka Y. Reverse genetics of influenza virus. Virol 2001 Sep 1; 287(2): 243–50CrossRef
51.
McAuley JL, Zhang K, McCullers JA. The effects of influenza A virus PB 1-F2 protein on polymerase activity are strain specific and do not impact pathogenesis. J Virol 2010 Jan; 84(1): 558–64PubMedCrossRef
52.
Khanna M, Kumar P, Prasad AK. Influenza and its role in apoptosis. Indian Journal of Allergy Asthma and Immunology 2001 Jan–Jun; 15(1): 7–12
53.
Uiprasertkul M, Kitphati R, Puthavathana P, et al. Apoptosis and pathogenesis of avian influenza A (H5N1) virus in humans. Emerg Infect Dis 2007; 13: 708–12PubMedCrossRef
54.
Herold S, Steinmueller M, von Wulffen W, et al. Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand. J Exp Med 2008; 205: 3065–77PubMedCrossRef
55.
Allen JE, Gardner SN, Vitalis EA, et al. Conserved amino acid markers from past influenza pandemic strains. BMC Microbiology 2009; 9: 77–100PubMedCrossRef
56.
Belshe RB, Morens DM. The origins of pandemic influenza: lessons from the 1918 virus. N Engl J Med 2005; 353: 2209–11PubMedCrossRef
57.
Finkelstein DB, Mukatira S, Mehta PK, et al. Persistent host markers in pandemic and H5N1 influenza viruses. J Virol 2007; 81: 10292–9PubMedCrossRef
58.
Chen GW, Chang SC, Mok CK, et al. Genomic signatures of human versus avian influenza A viruses. Emerg Infect Dis 2006; 12: 1353–60PubMedCrossRef
59.
Chaipan C, Kobasa D, Bertram S, et al. Proteolytic activation of the 1918 influenza virus hemagglutinin. J Virol 2009; 83(7): 3200–11PubMedCrossRef
60.
Stieneke-Gröber A, Vey M, Angliker H, et al. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J 1992 Jul; 11(7): 2407–14PubMed
61.
Reid AH, Fanning TG, Hultin JV, et al. Origin and evolution of the 1918 Spanish influenza virus hemagglutinin gene. Proc Natl Acad Sci U S A 1999; 96: 1651–6PubMedCrossRef
62.
Cohen J. Pandemic influenza: straight from the pig’s mouth. Swine research with swine influenzas. Science 2009 Jul 10; 325(5937): 140–1PubMedCrossRef
63.
Khiabanian H, Trifonov V, Rabadan R. Reassortment patterns in swine influenza viruses. PLoS One 2009; 4(10): 1–7CrossRef
64.
Qi X, Lu C. Swine influenza virus: evolution mechanism and epidemic characterization. A review [article in Chinese; abstract in English]. Wei Sheng Wu Xue Bao 2009 Sep 4; 49(9): 1138–45PubMed
65.
Hilleman MR. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine 2002; 20(25-26): 3068–87PubMedCrossRef
66.
De Jong JC, Rimmelzwaan GF, Fouchier RA, et al. Influenza virus: a master of metamorphosis. J Infect 2000; 40(3): 218–28PubMedCrossRef
67.
Ferguson NM, Galvani AP, Bush RM. Ecological and immunological determinants of influenza evolution. Nature 2003; 422(6930): 428–33PubMedCrossRef
68.
Varich NL, Gitel’man AK, Shilov AA, et al. Differential incorporation of genomic segments into the influenza A virus reassortants in mixed infection. Vopr Virusol 2009 Jan-Feb; 54(1): 7–11PubMed
69.
Nayak DP, Baloguna RA, Yamada H, et al. Influenza virus morphogenesis and budding. Virus Res 2009 Aug; 143(2): 147–61PubMedCrossRef
70.
Fitch WM, Leiter JM, Li XQ, et al. Positive Darwinian evolution in human influenza A viruses. Proc Natl Acad Sci U S A 1991 May 15; 88(10): 4270–4PubMedCrossRef
71.
Morens DM, Taubenberger JK, Harvey HA, et al. The 1918 influenza pandemic: lessons for 2009 and the future. Crit Care Med 2010 Apr; 38(4 Suppl.): e10–20PubMedCrossRef
72.
Suzuki Y, Nei M. Origin and evolution of influenza virus hemagglutinin genes. Mol Biol Evol 2002; 19: 501–9PubMedCrossRef
73.
Clemow FG. Epidemic influenza. Public Health 1889–90; 2: 358–67
74.
Clemow FG. The geography of disease. Cambridge: Cambridge University Press, 1903: 187–203
75.
Morens DM, Fauci AS. The 1918 influenza pandemic: insights for the 21st century. J Infect Dis 2007; 195: 1018–28PubMedCrossRef
76.
77.
Hilleman M. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine 2002; 20: 3068–87PubMedCrossRef
78.
Taubenberger JK, Morens DM. 1918 influenza: the mother of all pandemics. Emerg Infect Dis 2006; 12(1): 15–22PubMedCrossRef
79.
Cadham FT. The use of a vaccine in the recent epidemic of influenza. Can Med AssocJ 1919; 9: 519–27
80.
Beveridge WI. The chronicle of influenza epidemics. Hist Philos Life Sci 1991; 13(2): 223–34PubMed
81.
82.
Kilbourne ED, Smith C, Brett I, et al. The total influenza vaccine failure of 1947 revisited: major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic [published erratum appears in Proc Natl Acad Sci U S A 2003 Jan 21; 100 (2): 764]. Proc Natl Acad Sci U S A 2002 Aug 6; 99(16): 10748–52PubMedCrossRef
83.
84.
Kendall H. Vaccine innovation: lessons from World War II. J Public Health Policy 2006; 27(1): 38–57CrossRef
85.
86.
87.
Francis Jr T, Salk JE, Quilligan Jr JJ. Experience with vaccination against influenza in the spring of 1947. Am J Public Health 1947; 37: 1013-6
88.
89.
Viboud C, Tam T, Fleming D, et al. 1951 influenza epidemic, England and Wales, Canada, and the United States. Emerg Infect Dis 2006 Apr; 12(4): 661–8PubMedCrossRef
90.
Dauer CC, Serfling RE. Mortality from influenza 1957–1958 and 1959–1960. Am Rev Respir Dis 1961; 83(Suppl.): 15–28
91.
Henderson DA, Courtney B, Inglesby TV, et al. Public health and medical responses to the 1957–58 influenza pandemic. Biosecur Bioterror 2009; 7(3): 265–73PubMedCrossRef
92.
Williams MC, Davignon L, McDonald JC, et al. Trials of aqueous killed influenza vaccine in Canada, 1968–1969. Bull World Health Org 1973; 49: 333–40PubMed
93.
Alling DW, Blackwelder WC, Stuart-Harris CH. A study of excess mortality during influenza epidemics in the United States, 1968–1976. Am J Epidemiol 1981; 113: 30–43PubMed
94.
Knight V, Couch RB, Douglas RIG, et al. Serological responses and results of natural infectious challenge of recipients of zonal ultracentrifuged influenza A2/Aichi/2/68 vaccine. Bull World Health Org 1971; 45: 767–71PubMed
95.
Gaydos JC, Top FH, Hodder RA, et al. Swine influenza A outbreak, Fort Dix, New Jersey, 1976. Emerg Infect Disease 2006 Jan; 12(1): 23–8CrossRef
96.
Beveridge WIB. Where did red flu come from? New Scientist 1978; 23: 790–1
97.
Halperin W, Weiss WI, Altman R, et al. A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/75: report of a study and review of the literature. Am J Public Health 1979; 69: 1247–50PubMedCrossRef
98.
Pons VG, Canter J, Dolin R. Influenza A/USSR/77 (H1N1) on a university campus. Am J Epidemiol 2006; 111(1): 23–30
99.
Centers for Disease Control and Prevention. Influenza: People’s Republic of China. MMWR Morb Mortal Wkly Rep 1978; 27: 24
100.
Centers for Disease Control and Prevention. Influenza: United States, USSR, Hong Kong. MMWR Morb Mortal Wkly Rep 1978; 27: 16
101.
Zhdanov VM, Zakstelskaya LY, Isachenko VI, et al. Return of epidemic Al influenza virus. Lancet 1978; 1: 294–5PubMedCrossRef
102.
Kendal AP, Joseph JM, Kobayashi G, et al. Laboratory-based surveillance of influenza virus in the United States during the winter of 1977–1978:I. Periods of prevalence of H1N1 and H3N2 influenza A strains, their relative rates of isolation in different age groups, and detection of antigenic variants. Am J Epidemiol 1979; 110: 449–61PubMed
103.
Glezen WP, Keitel WA, Taber LH, et al. Age distribution of patients with medically attended illnesses caused by sequential variants of influenza A/H1N1: comparison to age-specific infection rates, 1978–1989. Am J Epidemiol 1991; 133: 296–304PubMed
104.
Mast EE, Harmon MW, Gravenstein S, et al. Emergence and possible transmission of amantadine resistant viruses during nursing home outbreaks of influenza A (H3N2). Am J Epidemiol 1991; 134(9): 988–77PubMed
105.
Centers for Disease Control and Prevention. Update on influenza activity — United States and worldwide, with recommendations for influenza vaccine composition for the 1988–89 season. MMWR Morb Mortal Wkly Rep 1988; 37: 241–4
106.
Webster RG, Peiris M, Chen H, et al. H5N1 outbreaks and enzootic influenza. Emerg Infect Dis 2006; 12: 3–8PubMedCrossRef
107.
Morens DM, Taubenberger JK, Folkers GK, et al. An historical antecedent of modern guidelines for community pandemic influenza mitigation. Public Health Rep 2009; 124: 22–5PubMed
108.
109.
110.
Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353: 1374–85CrossRef
111.
Kaverin NV, Rudneva IA, Govorkova EA, et al. Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. J Virol 2007; 81: 12911–7PubMedCrossRef
112.
Peiris JS, de Jong MD, Guan Y. Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev 2007; 20: 243–67PubMedCrossRef
113.
114.
Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent influenza A (H1N1) vaccine. N Engl J Med 2009: 361; 2405–13PubMedCrossRef
115.
116.
Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361(25): 2424–35PubMedCrossRef
117.
Braithwaite S, Handrigan MT. Novel H1N1 influenza. Emerg Med Rep 2010; 31:1–11
118.
119.
120.
Chien YW, Klugman KP, Morens DM. Efficacy of whole-cell killed bacterial vaccines in preventing pneumonia and death during the 1918 influenza pandemic. J Infect Dis 2010; 202(11): 1639–48PubMedCrossRef
121.
Rogers DE, Louria DB, Kilbourne ED. The syndrome of fatal influenza virus pneumonia. Trans Assoc Am Physicians 1958; 71: 260–73PubMed
122.
Choppin PW, Tamm I. Studies of two kinds of virus particles, which comprise influenza A2 virus strains: II. Reactivity with virus inhibitors in normal sera. J Exp Med 1960; 112: 921–44PubMedCrossRef
123.
Schulman JL, Kilbourne ED. Independent variation in nature of the hemagglutinin and neuraminidase antigens of influenza virus: distinctiveness of the hemagglutinin antigen of Hong Kong-68 virus. Proc Natl Acad Sci USA 1969; 63: 326–33PubMedCrossRef
124.
Stuart-Harris C. Epidemiology of influenza in man. Br Med Bull 1979; 35: 3–8PubMed
125.
Monto AS, Kendal AP. Effect of neuraminidase antibody on Hong Kong influenza. Lancet 1973; 1: 623–5PubMedCrossRef
126.
Viboud C, Grais RF, Lafont BA, et al.; Multinational Influenza Seasonal Morbidity Study Group. Multinational impact of the 1968 Hong Kong pandemic: evidence for a smoldering pandemic. J Infect Dis 2005; 192: 223–48
127.
128.
Igarashi M, Ito K, Yoshida R, et al. Predicting the antigenic structure of the pandemic (H1N1) 2009 influenza virus hemagglutinin. PLoS One 2010 Jan 1; 5(1): e8553PubMedCrossRef
129.
Krause JC, Tumpey TM, Huffman CJ, et al. Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. J Virol 2010 Mar; 84(6): 3127–30PubMedCrossRef
130.
Alexander DJ. An overview of the epidemiology of avian influenza. Vaccine 2007; 25: 5637–44PubMedCrossRef
131.
132.
Sambhara S, Poland GA. H5N1 avian influenza: preventive and therapeutic strategies against a pandemic. Ann Rev Med 2010; 61: 187–98PubMedCrossRef
133.
McCullers JA. Preparing for the next influenza pandemic. Pediatr Infect Dis J 2008 Oct; 27(10 Suppl.): S57–9PubMed
134.
Shope RE. Swine influenza: I. Experimental transmission and pathology. J Exp Med 1931; 54: 349–59PubMedCrossRef
135.
Shope RE. Swine influenza: III. Filtration experiments and etiology. J Exp Med 1931; 54: 373–85PubMedCrossRef
136.
Lewis PA, Shope RE. Swine influenza: II. A hemophilic bacillus from the respiratory tract of infected swine. J Exp Med 1931; 54: 361–71PubMedCrossRef
137.
Horsfall FL, Lennette EH, Rickard RE. A complex vaccine against influenza A virus. J Exp Med 1941; 73: 335–55PubMedCrossRef
138.
Horsfall Jr FL, Lennette EH. A complex vaccine effective against different strains of influenza virus. Science 1940; 91: 492–5PubMedCrossRef
139.
Horsfall FL, Lennette EH. The synergism of human influenza and canine distemper viruses in ferrets. J Exp Med 1941; 72: 247–59CrossRef
140.
Ginsberg HS, Horsfall FL. Concurrent infection with influenza virus and mumps virus or pneumonia virus of mice as bearing on the inhibition of virus multiplication by bacterial polysaccharides. J Exp Med 1949 Jan; 89(1): 37–52PubMedCrossRef
141.
142.
Legastelois I, Garcia-Sastre A, Palese P, et al. Preparation of genetically engineered A/H5N1 and A/H7N1 pandemic vaccine viruses by reverse genetics in a mixture of Vero and chicken embryo cells. Influenza Other Respir Viruses 2007 May; 1(3): 95–104CrossRef
143.
Biere B, Schweiger B. Molecular analyses of human influenza viruses: circulation of new variants since 1995/96. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2008 Sep; 51(9): 1050–60PubMedCrossRef
144.
Iwami S, Suzuki T, Takeuchi Y. Paradox of vaccination: is vaccination really effective against avian flu epidemics? PLoS One 2009; 4(3): e4915PubMedCrossRef
145.
Schweiger B, Bruns L, Meixenberger K. Reassortment between human A(H3N2) viruses is an important evolutionary mechanism. Vaccine 2006 Nov 10; 24(44-46): 6683–90PubMedCrossRef
146.
He CQ, Han GZ, Wang D, et al. Homologous recombination evidence in human and swine influenza A viruses. Virology 2008 Oct 10; 380(1): 12–20PubMedCrossRef
147.
148.
149.
Fiore AE, Shay DK, Broder K, et al.; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57(RR-7): 1–60PubMed
150.
151.
Lo AS, Zhu Q, Marasco WA. Intracellular antibodies (intrabodies) and their therapeutic potential. Handb Exp Pharmacol 2008; 181: 343–73PubMedCrossRef
152.
Mann A, Marriott AC, Balasingam S, et al. Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to reinfection. Vaccine 2006 May 15; 24(20): 4290–6PubMedCrossRef
153.
DeVincenzo JP. RNA interference strategies as therapy for respiratory viral infections. Pediatr Infect Dis J 2008 Oct; 27(10 Suppl.): S118–22PubMed
154.
Saravolac EG, Wong JP. Recent patents on development of nucleic acid-based antiviral drugs against seasonal and pandemic influenza virus infections. Recent Pat Antiinfect Drug Discov 2007 Jun; 2(2): 140–7PubMedCrossRef
155.
King Jr JC, Cox MM, Reisinger K, et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6–59 months. Vaccine 2009; 27(47): 6589–94PubMedCrossRef
156.
Mahmood K, Bright RA, Mytle N, et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 2008; 26(42): 5393–9PubMedCrossRef
157.
Drape RJ, Macklin MD, Barr LJ, et al. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 2006 May 22; 24(21): 4475–81PubMedCrossRef
158.
Schotsaert M, De FM, Fiers W, et al. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009; 8: 499–508PubMedCrossRef
159.
McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45: 1568–75PubMedCrossRef
160.
Furuse Y, Suzuki A, Shimizu M, et al. Reassortment between amantadine-resistant and -sensitive H1N1 influenza A viruses generated an amantadine-sensitive virus during the 2007–2008 season. J Infect Disease 2009 Dec 1; 200(11): 1766–73CrossRef
161.
162.
163.
Gerloff NA, Kremer JR, Mossong J, et al. Genomic diversity of oseltamivir-resistant influenza virus A (H1N1), Luxembourg, 2007–08. Emerg Infect Dis 2009 Sep; 15(9): 1523–4PubMedCrossRef
164.
Smee DF, Sidwell RW. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza. Exp Opin Investig Drugs 2002; 11(6): 859–69CrossRef
165.
166.
Webster RG, Kawaoka Y, Bean WJ, et al. Chemotherapy and vaccination: a possible strategy for the control of highly virulent influenza virus. J Virol 1985 July; 55(1): 173–6PubMed
167.
Longini Jr IM, Halloran ME, Nizam A, et al. Containing pandemic influenza with antiviral agents. Am J Epidemiol 2004; 159(7): 623–33PubMedCrossRef
168.
Dharan NJ, Patton M, Siston AM, et al. Outbreak of antiviral drug-resistant influenza A in long-term care facility, Illinois, USA, 2008. Emerg Infect Dis 2009 Dec; 15(12): 1973–6PubMedCrossRef
169.
Lazarev VN, Shmarov MM, Zakhartchouk AN, et al. Inhibition of influenza A virus reproduction by a ribozyme targeted against PB1 mRNA. Antiviral Res 1999 May; 42(1): 47–57PubMedCrossRef
170.
Sui HY, Zhao GY, Huang JD, et al. Small interfering RNA targetingm2 gene induces effective and long term inhibition of influenza A virus replication. PLoS One 2009 May 22; 4(5): e5671PubMedCrossRef
171.
172.
Wong JP, Christopher ME, Salazar AM, et al. Broad-spectrum and virus-specific nucleic acid-based antivirals against influenza. Front Biosci (Schol Ed) 2010 Jan 1; 2: 791–800
173.
Zhang S, Yan P, Winchester B, et al. Transmissibility of the 1918 pandemic influenza in Montreal and Winnipeg of Canada. Influenza Other Respi Viruses 2010 Jan; 4(1): 27–31PubMedCrossRef
174.
175.
Stohr K. Overview of the WHO Global Influenza Programme. Dev Biol (Basel) 2003; 115: 3–8
176.
177.
178.
179.
American Public Health Association. Influenza: report of a special committee of the American Public Health Association. J Am Med Assoc 1918; 71: 2068–73CrossRef
180.
Pottevin H. Rapport sur la pandémie grippale de 1918–1919 présenté au Comité Permanent de l’Office Internationale d’Hygiène Publique. Bulletin de l’Office Internationale d’Hygiène Publique 1921; 13: 125–81
181.
182.
Baral S, Sherman SG, Millson P, et al. Vaccine immunogenicity in injecting drug users: a systematic review. Lancet Infect Dis 2007; 7: 667–74PubMedCrossRef
183.
Boschini A, Longo B, Caselli F, et al. An outbreak of influenza in a residential drug-rehabilitation community. J Med Virol 2006; 78: 1218–22PubMedCrossRef
184.
Baral S, Sherman SG, Millson P, et al. Vaccine immunogenicity in injecting drug users: a systematic review. Lancet Infect Dis 2007 Oct; 7(10): 667–74PubMedCrossRef
185.
Stancliff S, Salomon N, Perlman DC, et al. Provision of influenza and pneumococcal vaccines to injection drug users at a syringe exchange. J Subst Abuse Treat 2000 Apr; 18(3): 263–5PubMedCrossRef
186.
Bragstad K, Nielsen LP, Fomsgaard A. The evolution of human influenza A viruses from 1999 to 2006: a complete genome study. Virol J 2008 Mar 7; 5: 40–53PubMedCrossRef
187.
Zarocostas J. External committee is to look at criticisms of WHO’s management of H1N1 pandemic. BMJ 2010; 340: 2342–3CrossRef
Metadaten
Titel
The Influenza Pandemic of 2009
Lessons and Implications
verfasst von
Professor Paul Shapshak
Francesco Chiappelli
Charurut Somboonwit
John Sinnott
Publikationsdatum
01.04.2011
Verlag
Springer International Publishing
Erschienen in
Molecular Diagnosis & Therapy / Ausgabe 2/2011
Print ISSN: 1177-1062
Elektronische ISSN: 1179-2000
DOI
https://doi.org/10.1007/BF03256397

Weitere Artikel der Ausgabe 2/2011

Molecular Diagnosis & Therapy 2/2011 Zur Ausgabe

Short Communication

Attitudes of Health Care Professionals Toward Pharmacogenetic Testing

Current Opinion

Blood-Based Protein Biomarkers for Diagnosis and Classification of Neurodegenerative Diseases

Short Communication

Enhanced Detection of Coxiella burnetii with a Complementary Locked Primer-Based Real-Time PCR Method

News

Journal Watch

Short Communication

Acute Bacterial Meningitis Cases Diagnosed by Culture and PCR in a Children’s Hospital Throughout a 9-Year Period (2000–2008) in Athens, Greece

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise